Mesocarb

Structural formula
General
Non-proprietary name	Mesocarb
other names	(Phenylcarbamoyl) [3- (1-phenylpropan-2-yl) -1,2,3-oxadiazol-3-ium-5-yl] azanide ( IUPAC ); Sidnocarb; Sydnocarb;
Molecular formula	C 18 H 18 N 4 O 2
External identifiers / databases
PubChem	71932
Wikidata	Q905058
Drug information
Drug class	stimulant
Mechanism of action	Inhibition of the reuptake of dopamine at the synaptic cleft
properties
Molar mass	322.36 g mol −1
safety instructions
GHS hazard labeling ; no classification available
GHS hazard labeling ; no classification available
Toxicological data	1780 mg kg −1 ( LD 50 , mouse , ip ) ; 1000 mg kg −1 ( LD 50 , mouse , oral ) ; 410 mg kg −1 ( LD 50 , rat , ip ) ; 450 mg kg −1 ( LD 50 , rat , oral ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Mesocarb ( INN ) is a synthetically produced stimulant and structurally belongs to the group of amphetamines .

history

The drug was developed in the Soviet Union in the 1970s and launched on January 1, 1974.

properties

Mesocarb acts as a dopamine reuptake inhibitor , which does not work as quickly as dextroamphetamine , but works longer and has a lower neurotoxic potential.

Mesocarb was used in Russia to treat ADHD or drug-induced sedation ; also as a sympathomimetic for circulatory weakness .

Legal position

Germany

In the Federal Republic of Germany, according to Annex II BtMG, mesocarb is a marketable but non-prescription narcotic, any possession without the permission of the Federal Institute for Drugs and Medical Devices (Federal Opium Agency) is a criminal offense.

Switzerland

In Switzerland, mesocarb is a controlled substance.

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ ^a ^b ^c ^d Entry on mesocarb in the ChemIDplus database of the United States National Library of Medicine (NLM) .
↑ IP Anokhina et al .: Characteristics of the central action of sidnocarb. In: Zhurnal Nevropatologii i Psikhiatrii Imeni SS Korsakova . Volume 74, Number 4, 1974, pp. 594-602, PMID 4825943 . (Russian).
↑ EA Anderzhanova et al .: Effect of d-amphetamine and sydnocarb on the extracellular level of dopamine, 3,4-dihydroxyphenylacetic acid, and hydroxyl radicals generation in rat striatum. In: Annals of the New York Academy of Sciences . Volume 914, September 2000, pp. 137-145, PMID 11085316 .
↑ R. Gainetdinov et al .: Effects of a psychostimulant drug sydnocarb on rat brain dopaminergic transmission in vivo. In: European Journal of Pharmacology . Volume 340, Number 1, December 1997, pp. 53-58, PMID 9527506 .
↑ II Afanas'ev et al .: Effects of amphetamine and sydnocarb on dopamine release and free radical generation in rat striatum. In: Pharmacology, Biochemistry and Behavior . Volume 69, Numbers 3-4, 2001 Jul-Aug, pp. 653-658, PMID 11509228 .
↑ Turova NF, Misionzhnik EIu, Ermolina LA, Aziavchik AV, Krasov VA: [Excretion of monoamines, their precursors and metabolites in the hyperactivity syndrome in mentally defective children] . In: Vopr Med Khim. . 34, No. 1, 1988, pp. 47-50. PMID 3369126 .
↑ Krasov VA: [Sidnocarb treatment of young school children with the hyperdynamic syndrome] . In: Zh Nevropatol Psikhiatr Im SS Korsakova . 88, No. 8, 1988, pp. 97-101. PMID 3195293 .
↑ AV Shpak, SA Appolonova, VA Semenov: Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. In: Journal of Chromatographic Science . Volume 43, Number 1, January 2005, pp. 11-21, PMID 15808002 .
↑ Federal Institute for Drugs and Medical Devices . (Excel file; 2 MB).
↑ Narcotics Description Ordinance.

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[ChemIDplus-2] Entry on mesocarb in the ChemIDplus database of the United States National Library of Medicine (NLM) .

[3] IP Anokhina et al .: Characteristics of the central action of sidnocarb. In: Zhurnal Nevropatologii i Psikhiatrii Imeni SS Korsakova . Volume 74, Number 4, 1974, pp. 594-602, PMID 4825943 . (Russian).

[4] EA Anderzhanova et al .: Effect of d-amphetamine and sydnocarb on the extracellular level of dopamine, 3,4-dihydroxyphenylacetic acid, and hydroxyl radicals generation in rat striatum. In: Annals of the New York Academy of Sciences . Volume 914, September 2000, pp. 137-145, PMID 11085316 .

[5] R. Gainetdinov et al .: Effects of a psychostimulant drug sydnocarb on rat brain dopaminergic transmission in vivo. In: European Journal of Pharmacology . Volume 340, Number 1, December 1997, pp. 53-58, PMID 9527506 .

[6] II Afanas'ev et al .: Effects of amphetamine and sydnocarb on dopamine release and free radical generation in rat striatum. In: Pharmacology, Biochemistry and Behavior . Volume 69, Numbers 3-4, 2001 Jul-Aug, pp. 653-658, PMID 11509228 .

[7] Turova NF, Misionzhnik EIu, Ermolina LA, Aziavchik AV, Krasov VA: [Excretion of monoamines, their precursors and metabolites in the hyperactivity syndrome in mentally defective children] . In: Vopr Med Khim. . 34, No. 1, 1988, pp. 47-50. PMID 3369126 .

[8] Krasov VA: [Sidnocarb treatment of young school children with the hyperdynamic syndrome] . In: Zh Nevropatol Psikhiatr Im SS Korsakova . 88, No. 8, 1988, pp. 97-101. PMID 3195293 .

[9] AV Shpak, SA Appolonova, VA Semenov: Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. In: Journal of Chromatographic Science . Volume 43, Number 1, January 2005, pp. 11-21, PMID 15808002 .

[10] Federal Institute for Drugs and Medical Devices . (Excel file; 2 MB).

[11] Narcotics Description Ordinance.